Medtronic chairman and CEO. The company's Diabetes segment showed notable improvement, with revenue increasing 10.4% organically. This was attributed to the continued adoption of the MiniMed 780G ...

So across Medtronic we continue to drive mid-single ... We're in the moment with 780G and diabetes, closed-loop technology and neuromodulation, and of course, PFA in our Cardiac Ablation Solutions ...

Medtronic plc MDT reported adjusted earnings ... U.S. revenues grew mid-single digits on the continued adoption of the MiniMed 780G automated insulin delivery system, with an increase in the ...

Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release ...

Medtronic's business spans several therapeutic ... A few years ago, it launched the MiniMed 780G, an innovative insulin pump that can automatically adjust insulin delivery based on patients ...

A clinician uses Medtronic's pulsed field ablation system for treating atrial fibrillation last month. On Tuesday, Medtronic reported adjusted quarterly net profit of $1.8 billion on $8.3 billion ...

Medtronic's surgical device sales decline due to inventory issues CEO Martha monitors impact of Trump's tariffs Shares down more than 7% in morning trade Feb 18 (Reuters) - Medtronic (MDT.N ...

Medtronic missed Wall Street's fiscal 2025 Q3 revenue estimate but beat earnings expectations. The company's revenue miss appears to be primarily related to a temporary change in distributor ...

Medtronic's strong fundamentals, consistent earnings surprises, and accelerating YoY revenue growth support my optimism for the upcoming earnings release and reinforce the "Buy" rating. The ...

VCG / Contributor / Getty Images Medtronic shares slumped Tuesday after the medical device maker missed sales forecasts. The revenue miss came as sales of its stapling and blood oxygen management ...